Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/14/2023 | $24.00 | Mkt Perform → Outperform | Barrington Research |
3/7/2023 | Outperform → Mkt Perform | Barrington Research | |
11/9/2022 | $31.00 | Mkt Perform → Outperform | Barrington Research |
10/14/2022 | $26.00 | Equal-Weight | Stephens |
3/9/2022 | Outperform → Mkt Perform | Barrington Research | |
3/9/2022 | Overweight → Equal-Weight | Stephens & Co. | |
3/9/2022 | $35.00 | Overweight → Equal-Weight | Stephens |
11/16/2021 | $55.00 | Overweight | Stephens & Co. |
10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa
BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve
Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00
Barrington Research downgraded Anika Therapeutics from Outperform to Mkt Perform
Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $31.00
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international OA Pain Management revenue growth of 17% Enhanced capital allocation strategy with new $40 million share repurchase program announced in May 2024; Continuing to optimize spending to support HA-based OA Pain Management and Regenerative Solutions growth BEDFORD, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a glob
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 1679035. A live audio webcast will be available in the Investor Relations section of Anika's website, w
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7%Join
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options ("Options") covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegat
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a dele
Sends Letter to Shareholders Reiterating Why Voting for Both Politan's "Highly Credible and Capable" Nominees Is Essential in Order to Safeguard Shareholder Value and Realize Masimo's Potential Highlights Key Facts Brought to Light During Discovery Process and Remains Confident That Masimo's Frivolous Legal Claims and Efforts to Reject Politan's Nomination Notice Will Be Defeated Shareholders Can Vote for Politan's Independent Nominees, Darlene Solomon and William Jellison, on the WHITE Card and Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Compan
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolioOver 300 surgeries completed during the limited market release, highlighting the growing interest and commercial demand across a wide range of tendon repairs
In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:ANIK), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Anika Therapeutics, presenting an average target of $30.0, a high estimate of $37.00, and a low estimate of $22.00. Consistency is reflected as the current
Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $24 price target.